Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Pcnsl (Ml)"'
Autor:
Ohka, Fumiharu, Yamaguchi, Junya, Motomura, Kazuya, Aoki, Kosuke, Nishikawa, Tomohide, Kibe, Yuji, Yamazaki, Shintaro, Natsume, Atsushi, Saito, Ryuta
Publikováno v:
Neuro-oncology Advances
Since 2020, tirabrutinib which is a Bruton’s tyrosine kinase (BTK) inhibitor has been available for recurrent or refractory PCNSL cases. The number of studies reporting efficiency and adverse effect of tirabrutinib treatment for recurrent or refrac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e9fb3ff01d00a5391bd9e86f57b20f0
https://doi.org/10.1093/noajnl/vdab159.090
https://doi.org/10.1093/noajnl/vdab159.090
Publikováno v:
Neuro-oncology Advances
Background: Primary central nervous system lymphoma (PCNSL) is a lymphoma whose primary lesion is localized in the brain and spinal cord. Treatment is a combination of high-dose methotrexate-based chemotherapy and whole-brain irradiation, often leadi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cedf0c4fb0704ba2fb4c735513d3ce1
http://europepmc.org/articles/PMC8648217
http://europepmc.org/articles/PMC8648217
Autor:
Sho Onodera, Jiro Akimoto
Publikováno v:
Neuro-oncology Advances
Tirabrutinib (TIR), a Burton’s tyrosine kinase inhibitory drug, has been approved in Japan for treating relapsed/refractory primary central nervous system lymphoma (PCNSL). The authors recently encountered three patients with newly diagnosed refrac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f09780cc4fd9632add34621fd9893b8
http://europepmc.org/articles/PMC8648228
http://europepmc.org/articles/PMC8648228
Autor:
Sasaki, Nobuyoshi, Kobayashi, Keiichi, Saito, Kuniaki, Onoda, Ryo, Seiya, Yosuke, Suzuki, Saki, Yamagishi, Yuki, Nakatomi, Hirofumi, Shiokawa, Yoshiaki, Nagane, Motoo
Publikováno v:
Neuro-oncology Advances
BACKGROUNDS: Tirabrutinib is a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, approved by the Japanese Pharmaceutical and Medical Devices Agency (PMDA) for relapsed and refractory PCNSL in March 2020. Skin-related disorder (SRD)s are t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcdce35060a9062a689ebac78605808c
https://doi.org/10.1093/noajnl/vdab159.091
https://doi.org/10.1093/noajnl/vdab159.091
Autor:
Mitsuya, Koichi, Deguchi, Shoichi, Muto, Manabu, Yasui, Kazuaki, Onoe, Tsuyoshi, Ogawa, Hirofumi, Hayashi, Kenji, Asakura, Hirofumi, Harada, Hideyuki, Hayashi, Nakamasa
Publikováno v:
Neuro-oncology Advances
BACKGROUND: Large brain metastases which require resection are treated with surgery followed by whole brain radiation therapy or postoperative stereotactic radiosurgery (SRS). Recently a novel strategy using neoadjuvant stereotactic radiosurgery (Na-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5665079b0541a956b7a2f0fe502c5c69
https://doi.org/10.1093/noajnl/vdab159.099
https://doi.org/10.1093/noajnl/vdab159.099
Publikováno v:
Neuro-oncology Advances
The majority of primary central nerve system (CNS) lymphomas (PCNSL) are diffuse large B-cell lymphomas. Anaplastic large cell lymphoma (ALCL) that is a type of T-cell tumor is very rare in the PCNSL. ALCLs are divided into two entities: anaplastic l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bfebdcc43b9cd50db4088bea6be688b
http://europepmc.org/articles/PMC8664643
http://europepmc.org/articles/PMC8664643
Autor:
Masasuke Ohno, Syunichiro Kuramitsu, Syohei Ito, Masayuki Kimata, Takumi Asai, Noriyuki Suzaki, Yasukazu Kajita, Tastuo Takahashi
Publikováno v:
Neuro-oncology Advances
Background: Although the risk of developing malignant lymphoma is higher in patients with rheumatoid arthritis (RA) than in the general population, the occurrence of primary central nervous system lymphoma (PCNSL) in patients with RA is extremely rar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::015316f4777227b04a0fb0ca656c7cde
http://europepmc.org/articles/PMC8664636
http://europepmc.org/articles/PMC8664636
Autor:
Mishima, Kazuhiko, Mitsuaki, Shirahata, Adachi, Junichi, Suzuki, Tomonari, Uchida, Eita, Nishikawa, Ryo
Publikováno v:
Neuro-oncology Advances
BACKGROUND: The prognosis of relapsed and refractory (r/r) primary CNS lymphoma (PCNSL) is poor, and the development of new therapeutic agents is desirable. Comprehensive genetic analysis of PCNSL has shown that MYD88 and CD79B are frequently mutated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50bcd46887a16e3535452b66d55d2195
https://doi.org/10.1093/noajnl/vdab159.089
https://doi.org/10.1093/noajnl/vdab159.089
Autor:
Hashiba, Tetsuo, Ueno, Katsuya, Naito, Nobuaki, Yamamura, Natsumi, Komori, Yumiko, Isozaki, Haruna, Lee, Ichi, Kamei, Takamasa, Takeda, Junnichi, Yoshimura, Kunikazu, Nonaka, Masahiro, Asai, Akio
Publikováno v:
Neuro-oncology Advances
Last year, the authors examined the outcome of the patients with metastatic brain tumor (MBT)treated by whole-brain irradiation (WBRT)or local irradiation (LRT)after surgery. As a result, it was shown that the overall survival (OS) was same but the r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::853d627861ffec17d772e67862038830
https://doi.org/10.1093/noajnl/vdab159.097
https://doi.org/10.1093/noajnl/vdab159.097
Autor:
Yamagishi Yuki, Nobuyoshi Sasaki, Yuko Matsushita, Saki Shimizu, Yoshie Matsumoto, Kuniaki Saito, Keiichi Kobayashi, Hirofumi Nakatomi, Yoshiaki Shiokawa, Koichi Ichimura, Motoo Nagane
Publikováno v:
Neuro-oncology Advances
Background: Treatment intervention for central nervous system lymphoma (CNSL) requires pathological diagnosis by surgical biopsy. However, there are some cases in which the risk of surgery is high due to age, comorbidities, localization of lesions, e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e147b34bda963b16b51ee6f32dda7f1
http://europepmc.org/articles/PMC8664634
http://europepmc.org/articles/PMC8664634